Mitochondria: A therapeutic target in acute kidney injury

Nephrology Dialysis Transplantation

Volumn 31, Issue 7, 2016, Pages 1062-1069

  Ishimoto, Yu ^a   Inagi, Reiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Acute kidney disease; Mitochondrial biogenesis; Mitochondrial fusion and fission; Mitophagy; Tubular damage

Indexed keywords

CYCLOSPORIN A; DYNAMIN RELATED PROTEIN 1; ELAMIPRETIDE; HYBRID PROTEIN; LEVOSIMENDAN; MITO CP; MITOCHONDRIAL DIVISION INHIBITOR 1; MITOCHONDRIAL DNA; MITOFUSIN 1; MITOFUSIN 2; MITOQ; NITRIC OXIDE; OPTIC ATROPY 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PEROXYNITRITE; PROTEIN INHIBITOR; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; RESVERATROL; SIRTUIN 1; SIRTUIN 3; SKQ 1; SKQR 1; SUPEROXIDE; UNCLASSIFIED DRUG; DRUG;

ACUTE KIDNEY FAILURE; APOPTOSIS; CELL FUNCTION; CELL FUSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG TARGETING; HUMAN; MITOCHONDRIAL BIOGENESIS; MITOCHONDRIAL DYNAMICS; MITOCHONDRION; MITOPHAGY; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; ACUTE KIDNEY INJURY; ANIMAL; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ACUTE KIDNEY INJURY; ANIMALS; HUMANS; MITOCHONDRIA; PHARMACEUTICAL PREPARATIONS;

EID: 84983753053     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv317     Document Type: Review

References (59)

1. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012;81:442-448
2. Bucaloiu ID, Kirchner HL, Norfolk ER et al. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int 2012;81:477-485
3. Susantitaphong P, Cruz DN, Cerda J et al. World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol 2013;8:1482-1493
4. Soltoff SP. ATP and the regulation of renal cell function. Annu Rev Physiol 1986;48:9-31
5. Linkermann A, Chen G, Dong G et al. Regulated cell death in AKI. JAmSoc Nephrol 2014;25:2689-2701
6. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448-1460
7. Venkatachalam MA, Weinberg JM. The tubule pathology of septic acute kidney injury: a neglected area of research comes of age. Kidney Int 2012;81:338-340
8. Virbasius CA, Virbasius JV, Scarpulla RC. NRF-1, an activator involved in nuclear-mitochondrial interactions, utilizes a new DNA-binding domain conserved in a family of developmental regulators. Genes Dev 1993;7:2431-2445
9. Virbasius JV, Virbasius CA, Scarpulla RC. Identity of GABP with NRF-2, a multisubunit activator of cytochrome oxidase expression, reveals a cellular role for an ETS domain activator of viral promoters. Genes Dev 1993;7:380-392
10. Zhang L, Ding Q, Wang Z. Nuclear respiratory factor 1 mediates the transcription initiation of insulin-degrading enzyme in a TATA box-binding protein-independent manner. PLoS ONE 2012;7:e42035
11. Leal MC, Magnani N, Villordo S et al. Transcriptional regulation of insulin-degrading enzyme modulates mitochondrial amyloid â (Aâ) peptide catabolism and functionality. J Biol Chem 2013;288:12920-12931
12. Pandit A, Vadnal J, Houston S et al. Impaired regulation of electron transport chain subunit genes by nuclear respiratory factor 2 in multiple sclerosis. J Neurol Sci 2009;279:14-20
13. Wu Z, Puigserver P, Andersson U et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999;98:115-124
14. Rasbach KA, Schnellmann RG. Signaling of mitochondrial biogenesis following oxidant injury. J Biol Chem 2007;282:2355-2362
15. Westermann B. Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol 2010;11:872-884
16. Tatsuta T, Langer T. Quality control of mitochondria: protection against neurodegeneration and ageing. EMBO J 2008;27:306-314
17. Archer SL. Mitochondrial dynamics-mitochondrial fission and fusion in human diseases. N Engl J Med 2013;369:2236-2251
18. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol 2011;12:9-14
19. Ryan BJ, Hoek S, Fon EA et al. Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. Trends Biochem Sci 2015;40:200-210
20. Parikh SM, Yang Y, He L et al. Mitochondrial function and disturbances in the septic kidney. Semin Nephrol 2015;35:108-119
21. O'Toole JF. Renal manifestations of genetic mitochondrial disease. Int J Nephrol Renovasc Dis 2014;7:57-67
22. Liang H, Ward WF. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ 2006;30:145-151
23. Rasbach KA, Schnellmann RG. PGC-1alpha over-expression promotes recovery from mitochondrial dysfunction and cell injury. BiochemBiophys Res Commun 2007;355:734-739
24. Tran M, Tam D, Bardia D et al. PGC-1á promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest 2011;121:4003-4014
25. Detmer SA, Chan DC. Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Biol 2007;8:870-879
26. Brooks C, Wei Q, Cho SG et al. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest 2009;119:1275-1285
27. Gall JM, Wang Z, Liesa M et al. Role of mitofusin 2 in the renal stress response. PLoS ONE 2012;7:e31074
28. Ishihara M, Urushido M, Hamada K et al. Sestrin-2 and BNIP3 regulate autophagy and mitophagy in renal tubular cells in acute kidney injury. Am J Physiol Renal Physiol 2013;305:F495-F509
29. Jiang M, Wei Q, Dong G et al. Autophagy in proximal tubules protects against acute kidney injury. Kidney Int 2012;82:1271-1283
30. Takasu O, Gaut JP, Watanabe E et al. Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. Am J Respir Crit Care Med 2013;187:509-517
31. Hoshino A, Mita Y, Okawa Y et al. Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart. Nat Commun 2013;4:2308
32. Rodgers JT, Lerin C, Gerhart-Hines Z et al. Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett 2008;582:46-53
33. Brenmoehl J, Hoeflich A. Dual control of mitochondrial biogenesis by sirtuin 1 and sirtuin 3. Mitochondrion 2013;3:755-761
34. Cantó C, Gerhart-Hines Z, Feige JN et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009;458:1056-1060
35. Morigi M, Perico L, Rota C et al. Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. J Clin Invest 2015;125:715-726
36. Wang H, Guan Y, Karamercan MA et al. Resveratrol rescues kidney mitochondrial function following hemorrhagic shock. Shock 2015;44:173-180
37. Tang WX, Wu WH, Qiu HY et al. Amelioration of rhabdomyolysisinduced renal mitochondrial injury and apoptosis through suppression of Drp-1 translocation. J Nephrol 2013;26:1073-1082
38. Sumida M, Doi K, Ogasawara E et al. Regulation of mitochondrial dynamics by dynamin-related protein-1 in acute cardiorenal syndrome. J Am Soc Nephrol 2015; doi: 10.1681/ASN.2014080750
39. Gall JM, Wang Z, Bonegio RG et al. Conditional knockout of proximal tubule mitofusin 2 accelerates recovery and improves survival after renal ischemia. J Am Soc Nephrol 2015;26:1092-1102
40. Orrenius S, Gogvadze V, Zhivotovsky B. Mitochondrial oxidative stress: implications for cell death. Annu Rev Pharmacol Toxicol 2007;47:143-183
41. Richter C, Park JW, Ames BN. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci USA 1988;85:6465-6467
42. Mukhopadhyay P, Horváth B, Zsengellér Z et al. Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. Free Radic Biol Med 2012;52:497-506
43. Plotnikov EY, Silachev DN, Jankauskas SS et al. Mild uncoupling of respiration and phosphorylation as a mechanism providing nephro- and neuroprotective effects of penetrating cations of the SkQ family. Biochemistry (Mosc) 2012;77:1029-1037
44. Dare AJ, Bolton EA, Pettigrew GJ et al. Protection against renal ischemia-reperfusion injury in vivo by the mitochondria targeted antioxidant MitoQ. Redox Biol 2015;5:163-168
45. Bonora M, Wieckowski MR, Chinopoulos C et al. Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition. Oncogene 2015;34:1475-1486
46. Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol 2013;37:602-612
47. Piot C, Croisille P, Staat P et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-481
48. Cho SG, Du Q, Huang S et al. Drp1 dephosphorylation in ATP depletion-induced mitochondrial injury and tubular cell apoptosis. Am J Physiol Renal Physiol 2010;299:F199-F206
49. Devalaraja-Narashimha K, Diener AM, Padanilam BJ. Cyclophilin D gene ablation protects mice from ischemic renal injury. Am J Physiol Renal Physiol 2009;297:F749-F759
50. Guan N, Ren YL, Liu XY et al. Protective role of cyclosporine A and minocycline on mitochondrial disequilibrium-related podocyte injury and proteinuria occurrence induced by adriamycin. Nephrol Dial Transplant 2015;30:957-969
51. Wang J, Biju MP, Wang MH et al. Cytoprotective effects of hypoxia against cisplatin-induced tubular cell apoptosis: involvement of mitochondrial inhibition and p53 suppression. J Am Soc Nephrol 2006;17:1875-1885
52. Cui J, Bai XY, Sun X et al. Rapamycin protects against gentamicin-induced acute kidney injury via autophagy in mini-pig models. Sci Rep 2015;5:11256
53. Strappazzon F, Nazio F, Corrado M et al. AMBRA1 is able to induce mitophagy via LC3 binding, regardless of PARKIN and p62/SQSTM1. Cell Death Differ 2015;22:517
54. Birk AV, Liu S, Soong Y et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol 2013;24:1250-1261
55. Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol 2004;68:807-812
56. Torraco A, Carrozzo R, Piemonte F et al. Effects of levosimendan on mitochondrial function in patients with septic shock: a randomized trial. Biochimie 2014;102:166-173
57. Papp Z, Édes I, Fruhwald S et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 2012;159:82-87
58. Gamilla-Crudo AK, Kadambi PV, Prough DS. Test driving levosimendan as the new "kidney protector": first impressions. Crit Care Med 2013;41:2445-2446
59. Inagi R, Ishimoto Y, Nangaku M. Proteostasis in endoplasmic reticulum-new mechanisms in kidney disease. Nat Rev Nephrol 2014;10:369-378